Life AI Net
ホーム
アーカイブ
計算ツール
ディレクトリ
ニュースレター
Hot
ログイン
日本語
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
ホーム
アーカイブ
計算ツール
ディレクトリ
ニュースレター
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
ログイン
ホーム
アーカイブ
計算ツール
ディレクトリ
More
ライブ
FierceBiotech
Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board
FierceBiotech
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
BioWorld
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld
Shanghai Meiyue Biotech Development presents new molecular glue degraders
BioWorld
Jiangsu Carephar Pharmaceutical describes new AT2 receptor agonists
BioWorld
Pharma industry faces long haul to get return on investment from AI
FierceBiotech
Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
Thermo Fisher
Thermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo Finance
Agilent
Does Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st
10x Genomics Blog
Why 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance
10x Genomics Blog
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpace
Thermo Fisher
Thermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking Alpha
FierceBiotech
Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board
FierceBiotech
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
BioWorld
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld
Shanghai Meiyue Biotech Development presents new molecular glue degraders
BioWorld
Jiangsu Carephar Pharmaceutical describes new AT2 receptor agonists
BioWorld
Pharma industry faces long haul to get return on investment from AI
FierceBiotech
Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
Thermo Fisher
Thermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo Finance
Agilent
Does Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st
10x Genomics Blog
Why 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance
10x Genomics Blog
LiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpace
Thermo Fisher
Thermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking Alpha
アーカイブ
BioWorld
2025年12月18日
Financings for Dec. 18, 2025
Financings for Dec. 18, 2025
原文
本文は利用できません。元の情報源をご確認ください。